The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | Pros and cons of increasing CD38 expression
Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses the pros and cons of increasing CD38 expression at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The role of CD38 expression in myeloma cells is still unclear, however, it is currently thought that a high expression leads to an increased response from daratumumab. There are current ongoing trials using drugs to increase CD38 expression, to test this theory. Dr Plesner states that he is concerned about increasing CD38 expression, as it may lead to resistance to other treatments.
